BR112017016638A2 - anticorpos direcionados contra o gene de ativação de linfócitos 3 (lag-3) - Google Patents
anticorpos direcionados contra o gene de ativação de linfócitos 3 (lag-3)Info
- Publication number
- BR112017016638A2 BR112017016638A2 BR112017016638A BR112017016638A BR112017016638A2 BR 112017016638 A2 BR112017016638 A2 BR 112017016638A2 BR 112017016638 A BR112017016638 A BR 112017016638A BR 112017016638 A BR112017016638 A BR 112017016638A BR 112017016638 A2 BR112017016638 A2 BR 112017016638A2
- Authority
- BR
- Brazil
- Prior art keywords
- lag
- directed against
- antibodies directed
- lymphocyte activation
- activation gene
- Prior art date
Links
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 title 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 title 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111486P | 2015-02-03 | 2015-02-03 | |
US62/111,486 | 2015-02-03 | ||
PCT/US2016/016424 WO2016126858A2 (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017016638A2 true BR112017016638A2 (pt) | 2018-06-19 |
BR112017016638B1 BR112017016638B1 (pt) | 2023-11-07 |
Family
ID=56564868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017016638-0A BR112017016638B1 (pt) | 2015-02-03 | 2016-02-03 | Agente de ligação do gene de ativação de linfócitos-3, uso do mesmo e composição farmacêutica |
Country Status (15)
Country | Link |
---|---|
US (3) | US10836824B2 (pt) |
EP (2) | EP4011914A1 (pt) |
JP (1) | JP6949713B2 (pt) |
KR (1) | KR20170116067A (pt) |
CN (2) | CN107428836A (pt) |
BR (1) | BR112017016638B1 (pt) |
CA (1) | CA2975753A1 (pt) |
EA (1) | EA201791742A1 (pt) |
HK (2) | HK1246814A1 (pt) |
IL (1) | IL253718B (pt) |
MA (1) | MA41463A (pt) |
MX (2) | MX2017009904A (pt) |
SG (2) | SG10201907161YA (pt) |
WO (1) | WO2016126858A2 (pt) |
ZA (1) | ZA201705303B (pt) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
JP7212821B2 (ja) | 2016-10-13 | 2023-01-26 | チア・タイ・ティエンチン・ファーマシューティカル・グループ・カンパニー・リミテッド | 抗lag-3抗体および組成物 |
BR112019008861A2 (pt) | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3) |
AU2017354070A1 (en) | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
CA3049536A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
CN110650974B (zh) | 2017-02-10 | 2024-04-19 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
EP3389702A4 (en) | 2017-02-22 | 2019-08-14 | I-Mab | ANTI-LAG-3 ANTIBODIES AND USES THEREOF |
KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
CA3185303A1 (en) * | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-a, tim-3, and lag-3 |
MX2019011916A (es) | 2017-04-05 | 2020-01-09 | Hoffmann La Roche | Anticuerpos anti-lag3. |
KR102346336B1 (ko) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
BR112019022515A2 (pt) | 2017-04-27 | 2020-06-16 | Tesaro, Inc. | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos |
JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ, インコーポレイテッド | 癌を処置する併用療法 |
SI3631454T1 (sl) | 2017-05-30 | 2023-12-29 | Bristol-Myers Squibb Company | Zdravljenje lag-3 pozitivnih tumorjev |
EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
CA3073733A1 (en) | 2017-08-30 | 2019-03-07 | Phanes Therapeutics, Inc. | Anti-lag-3 antibodies and uses thereof |
EP3687505A1 (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Niraparib formulations |
SG11202002862RA (en) | 2017-09-30 | 2020-04-29 | Tesaro Inc | Combination therapies for treating cancer |
MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
US20200354457A1 (en) | 2018-01-31 | 2020-11-12 | Hoffmann-La Roche Inc. | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
US11661452B2 (en) | 2018-03-20 | 2023-05-30 | WuXi Biologics Ireland Limited | Anti-lag-3 antibody polypeptide |
CN110305215B (zh) * | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
KR102250234B1 (ko) * | 2018-06-29 | 2021-05-10 | 주식회사 와이바이오로직스 | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 |
CN112739371A (zh) | 2018-07-26 | 2021-04-30 | 百时美施贵宝公司 | 用于治疗癌症的lag-3组合疗法 |
TW202024638A (zh) | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
EP3860988A1 (en) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
TW202028181A (zh) | 2018-10-03 | 2020-08-01 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)鹽 |
SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
CN112010972B (zh) * | 2019-05-31 | 2023-01-10 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CA3153777A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
CA3160479A1 (en) | 2019-11-08 | 2021-05-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
KR20220129548A (ko) | 2019-12-18 | 2022-09-23 | 테사로, 인코포레이티드 | 생물제약 조성물 및 관련 방법 |
JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | Il-10およびその使用 |
KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
JP2023540255A (ja) | 2020-08-28 | 2023-09-22 | ブリストル-マイヤーズ スクイブ カンパニー | 肝細胞癌のためのlag-3アンタゴニスト療法 |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
IL303648A (en) | 2020-12-28 | 2023-08-01 | Bristol Myers Squibb Co | Antibody preparations and methods of using them |
WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
CN112852870B (zh) * | 2021-01-13 | 2022-03-04 | 北京鼎成肽源生物技术有限公司 | IL-18基因融合H2Kk基因在制备增强细胞免疫的细胞中的应用、细胞及制备方法 |
WO2022166987A1 (zh) * | 2021-02-08 | 2022-08-11 | 迈威(上海)生物科技股份有限公司 | 结合lag-3的抗体及其用途 |
KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
EP4337694A1 (en) | 2021-05-12 | 2024-03-20 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
CN113603779B (zh) * | 2021-08-18 | 2023-06-02 | 深圳市元谷生物科技有限公司 | 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
CN114874324B (zh) * | 2022-05-13 | 2023-02-03 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用 |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
USRE38313E1 (en) * | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
JP2006523226A (ja) | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | T細胞調節方法 |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EA034778B1 (ru) * | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Антитела к cd47 и способы их применения |
UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
AU2014230741B2 (en) * | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
EP3119913B1 (en) | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
WO2015179799A1 (en) | 2014-05-22 | 2015-11-26 | The General Hospital Corporation | DD1alpha RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
CN115023443A (zh) * | 2020-01-29 | 2022-09-06 | 肯乔克蒂生物技术股份有限公司 | 抗mdr1抗体及其用途 |
-
2016
- 2016-02-02 MA MA041463A patent/MA41463A/fr unknown
- 2016-02-03 SG SG10201907161YA patent/SG10201907161YA/en unknown
- 2016-02-03 CN CN201680020117.3A patent/CN107428836A/zh active Pending
- 2016-02-03 BR BR112017016638-0A patent/BR112017016638B1/pt active IP Right Grant
- 2016-02-03 JP JP2017540834A patent/JP6949713B2/ja active Active
- 2016-02-03 EP EP21198994.2A patent/EP4011914A1/en active Pending
- 2016-02-03 CN CN202210381152.5A patent/CN114634573A/zh active Pending
- 2016-02-03 KR KR1020177024728A patent/KR20170116067A/ko not_active Application Discontinuation
- 2016-02-03 EA EA201791742A patent/EA201791742A1/ru unknown
- 2016-02-03 US US15/548,405 patent/US10836824B2/en active Active
- 2016-02-03 CA CA2975753A patent/CA2975753A1/en active Pending
- 2016-02-03 SG SG11201706199RA patent/SG11201706199RA/en unknown
- 2016-02-03 WO PCT/US2016/016424 patent/WO2016126858A2/en active Application Filing
- 2016-02-03 MX MX2017009904A patent/MX2017009904A/es unknown
- 2016-02-03 EP EP16747220.8A patent/EP3253798A4/en not_active Ceased
-
2017
- 2017-07-30 IL IL253718A patent/IL253718B/en unknown
- 2017-07-31 MX MX2022000112A patent/MX2022000112A/es unknown
- 2017-08-04 ZA ZA2017/05303A patent/ZA201705303B/en unknown
-
2018
- 2018-05-17 HK HK18106454.6A patent/HK1246814A1/zh unknown
- 2018-05-25 HK HK18106890.8A patent/HK1247618A1/zh unknown
-
2019
- 2019-05-01 US US16/400,198 patent/US20190256596A1/en not_active Abandoned
-
2020
- 2020-10-19 US US17/074,269 patent/US20210095026A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1247618A1 (zh) | 2018-09-28 |
WO2016126858A3 (en) | 2016-09-29 |
MA41463A (fr) | 2017-12-12 |
EA201791742A1 (ru) | 2018-01-31 |
MX2022000112A (es) | 2022-02-10 |
EP4011914A1 (en) | 2022-06-15 |
HK1246814A1 (zh) | 2018-09-14 |
BR112017016638B1 (pt) | 2023-11-07 |
ZA201705303B (en) | 2022-12-21 |
US10836824B2 (en) | 2020-11-17 |
SG11201706199RA (en) | 2017-08-30 |
US20190256596A1 (en) | 2019-08-22 |
US20180127496A1 (en) | 2018-05-10 |
KR20170116067A (ko) | 2017-10-18 |
CA2975753A1 (en) | 2016-08-11 |
IL253718A0 (en) | 2017-09-28 |
CN114634573A (zh) | 2022-06-17 |
EP3253798A4 (en) | 2018-07-25 |
JP6949713B2 (ja) | 2021-10-13 |
EP3253798A2 (en) | 2017-12-13 |
CN107428836A (zh) | 2017-12-01 |
MX2017009904A (es) | 2018-06-27 |
IL253718B (en) | 2021-08-31 |
US20210095026A1 (en) | 2021-04-01 |
SG10201907161YA (en) | 2019-09-27 |
WO2016126858A2 (en) | 2016-08-11 |
JP2018505674A (ja) | 2018-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017016638A2 (pt) | anticorpos direcionados contra o gene de ativação de linfócitos 3 (lag-3) | |
HK1249023A1 (zh) | Pd-l1("程序性死亡配體1")抗體 | |
DK3361575T3 (da) | Konnektor | |
BR112016016020A2 (pt) | anticorpos dirigidos contra interleucina-33 (il-33) | |
MA42036A (fr) | Analogues nucléosidiques 5'-substitués | |
FR3036037B1 (fr) | Harnais d'encordement perfectionne | |
FR3049869B1 (fr) | Harnais | |
FR3032419B1 (fr) | Pointe arriere d'aeronef | |
NO343600B1 (no) | Innhegning for oppdrettsanlegg | |
PT3531824T (pt) | Proteínas inseticidas | |
EP3172324A4 (en) | 5'-triphosphate oligoribonucleotides | |
HK1258580A1 (zh) | 避免出血的微電極 | |
MA50025A (fr) | Nucléosides de spirothiétane | |
DK3478843T3 (da) | Oligonukleotider omfattende modificerede nukleosider | |
DK3791095T3 (da) | Proceskomponent | |
DE112018004675A5 (de) | Vorrichtung zum Puffern von Kleinteilen | |
AU2016215291B2 (en) | Antibodies directed against Lymphocyte Activation Gene 3 (LAG-3) | |
AU2016215291A1 (en) | Antibodies directed against Lymphocyte Activation Gene 3 (LAG-3) | |
AU2016905210A0 (en) | Electronic Lure Activation System | |
ES1185533Y (es) | Estructura de frontón | |
ES1199108Y (es) | Lito perfeccionado | |
KR20180085038A (ko) | 커넥터 | |
IT201700000974U1 (it) | Cannula per ecmo veno-venoso | |
BR112017025984A2 (pt) | manipulador de matéria com revestimento condutor. | |
AU2015904525A0 (en) | Anti-CCR6 antibodies (2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2016, OBSERVADAS AS CONDICOES LEGAIS |